Reported Earnings • Mar 02
First half 2026 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 1H 2025) First half 2026 results: AU$0.011 loss per share (improved from AU$0.012 loss in 1H 2025). Revenue: AU$4.13m (down 4.7% from 1H 2025). Net loss: AU$629.2k (loss narrowed 8.4% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Board Change • Jan 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Chairman Stuart Smith was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Aankondiging • Oct 24
Global Health Limited, Annual General Meeting, Nov 25, 2025 Global Health Limited, Annual General Meeting, Nov 25, 2025. Location: scottish house , 90 william street, melbourne vic 3000, melbourne Australia Reported Earnings • Aug 29
Full year 2025 earnings released: AU$0.015 loss per share (vs AU$0.023 loss in FY 2024) Full year 2025 results: AU$0.015 loss per share (improved from AU$0.023 loss in FY 2024). Revenue: AU$8.67m (flat on FY 2024). Net loss: AU$866.6k (loss narrowed 34% from FY 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. New Risk • Aug 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$707k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$707k free cash flow). Negative equity (-AU$3.7m). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (AU$5.39m market cap, or US$3.53m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change). Reported Earnings • Feb 27
First half 2025 earnings released: AU$0.012 loss per share (vs AU$0.019 loss in 1H 2024) First half 2025 results: AU$0.012 loss per share (improved from AU$0.019 loss in 1H 2024). Revenue: AU$4.33m (up 7.3% from 1H 2024). Net loss: AU$686.8k (loss narrowed 39% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Aankondiging • Feb 10
Global Health Limited Announces Resignation of Karen Corry as Non-Executive Director Global Health Limited announced Resignation of Karen Corry as Non-Executive Director, effective February 10, 2025. His last date of notice is November 19, 2024. During her tenure of three and a half years, she chaired the Audit Committee and focused on the strategic direction and transition of the MasterCare product suite. New Risk • Jan 17
New major risk - Revenue and earnings growth Earnings have declined by 45% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$2.9m). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (AU$7.55m market cap, or US$4.69m). Board Change • Jan 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Karen Corry was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Aankondiging • Jan 06
Global Health Limited Announces Resignation of Steven Strange as Non- Executive Director Global Health Limited announced that Steven Strange has resigned as a Non- Executive Director as at 2 January 2025. Date of last notice was 18 August, 2024. Aankondiging • Oct 18
Global Health Limited, Annual General Meeting, Nov 19, 2024 Global Health Limited, Annual General Meeting, Nov 19, 2024. Location: scottish house, 90 william street, melbourne vic 3000, Australia Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.023 loss per share (vs AU$0.14 loss in FY 2023) Full year 2024 results: AU$0.023 loss per share (improved from AU$0.14 loss in FY 2023). Revenue: AU$8.67m (up 11% from FY 2023). Net loss: AU$1.31m (loss narrowed 84% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year whereas the company’s share price has fallen by 38% per year. Aankondiging • Aug 29
Global Health Limited announced that it has received $0.354 million in funding Global Health Limited announced a private placement that it has issued convertible notes for the gross proceeds of $354,000 on August 28, 2024. The company issued $250,000 of Convertible Notes to company's Directors and $104,000 of convertible notes to sophisticated investors. This investment brings the total raised funds from convertible notes to $1,000,000. Aankondiging • Oct 20
Global Health Limited, Annual General Meeting, Nov 21, 2023 Global Health Limited, Annual General Meeting, Nov 21, 2023, at 15:00 AUS Eastern Standard Time. Location: Level 18 Bourke Place, 600 Bourke Street, Melbourne Victoria Australia Agenda: To consider Remuneration Report 2023; to consider Re-election of Director; to consider Approval of Issue of Equity Securities under Employee Incentive Plan; and to consider Special Resolution for Approval of Additional 10% Placement Capacity under Listing Rule 7.1A. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.14 loss per share (vs AU$0.037 loss in FY 2022) Full year 2023 results: AU$0.14 loss per share (further deteriorated from AU$0.037 loss in FY 2022). Revenue: AU$7.82m (up 20% from FY 2022). Net loss: AU$8.05m (loss widened 293% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.0m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 0.3% per year over the past 5 years. Market cap is less than US$10m (AU$8.13m market cap, or US$5.27m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.8m revenue, or US$4.4m). Reported Earnings • Feb 28
First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.025 loss in 1H 2022) First half 2023 results: AU$0.048 loss per share (further deteriorated from AU$0.025 loss in 1H 2022). Revenue: AU$3.18m (up 8.6% from 1H 2022). Net loss: AU$2.71m (loss widened 94% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Aankondiging • Jan 30
Global Health Limited Announces Company Secretary Changes Global Health Limited announced that James Barrie has been appointed as Company Secretary effective from January 31, 2023. James is anexperienced Company Secretary, having spent the last 25 years working with many ASX-listed companies across a variety of industry sectors. Sam Butcher has resigned as Company Secretary with effect from January 31, 2023. Aankondiging • Nov 17
Global Health Limited Announces Management Changes Global Health Limited announced that Chief Executive Officer Michael Davies will be leaving his role effective immediately. Michael has led Global Health during a very challenging period of a global pandemic, and with global and domestic challenges faced by the organisation, it is necessary to restructure the organisation for its ongoing sustainability and to continue its growth path. Mathew Cherian, the founder, major shareholder, and Executive Director of Global Health has been appointed Group Managing Director and tasked with implementing the necessary restructure and cost efficiencies. Mathew has worked closely with the Global Health executive team for many years and over the past 16 months has spearhead the move into the Asia Pacific Region resulting in the key appointments announced to the ASX on 15th August of a Regional ASEAN CEO and on 7 Th September a well credentialed Non-Executive Director of Global Health (Australia) Pte Ltd, Singapore. Having an intimate working knowledge of both the Australian market operations and with an experienced team in place to drive both local and overseas expansion, Mathew has the unique insights and combination of skill sets required to oversee Global Health's growth forward. Recent Insider Transactions Derivative • Nov 16
Executive Director exercised options to buy AU$240k worth of stock. On the 9th of November, Alumootil Mathew Cherian exercised options to buy 800k shares at a strike price of around AU$0.25, costing a total of AU$200k. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. Since June 2022, Alumootil Mathew has owned 23.38m shares directly. Company insiders have collectively bought AU$230k more than they sold, via options and on-market transactions, in the last 12 months. Aankondiging • Oct 22
Global Health Limited, Annual General Meeting, Nov 23, 2022 Global Health Limited, Annual General Meeting, Nov 23, 2022, at 15:00 AUS Eastern Standard Time. Location: Australian Institute of Company Directors Business Centre Level 26, 367 Collins St, Melbourne, Victoria 3000 Melbourne Victoria Australia Agenda: To consider the Annual Financial Report, the Directors' Report and the Independent Audit Report of the Company and its controlled entities for the financial year ended 30 June 2022; to consider Remuneration Report 2022; to consider Election of Director; to consider Re-election of Director; to consider Special Resolution for Approval of Additional 10% Placement Capacity under Listing Rule 7.1A; and to consider other matters. Aankondiging • Sep 07
Global Health (Australia) Pte Ltd Appoints Martin Murnaghan as Non-Executive Director Global Health Limited announced the appointment of experienced IT executive Martin Murnaghan as Non-Executive Director, Global Health (Australia) Pte Ltd, Singapore to help develop international markets for the Company's portfolio of next generation healthcare platforms based on Global Health's patient-centric Community platforms. Mr. Murnaghan, who is based in Europe, will join Mathew Cherian and Steven Pynt on the board of Global Health (Australia) Pte Ltd, the Company's Singapore subsidiary. He will assist in identifying opportunities across Europe, the Middle East, Africa and the Caribbean regions and will help lead the upgrade and integration of Global Health's personal health record deployed on smart phones as the primary device that connects consumers to their healthcare teams. Appointment of Mr. Martin Murnaghan as Non-Executive Director, Global Health (Australia) Pte Ltd, Singapore Mr. Murnaghan has enjoyed a career spanning 45 years in IT and Banking, having co-founded `Reg-Tech' software business Vizor Software and served as CEO, Executive Vice Chairman and Chairman, Middle East. Mr. Murnaghan has extensive experience working with Government and financial institutions in over 30 jurisdictions and has been involved in major enterprise software transactions in 48 countries throughout his distinguished career. These important connections and business dealings over a long career, bring a wealth of experience in successfully operating and closing deals in the international markets sphere. Reported Earnings • Sep 01
Full year 2022 earnings released: AU$0.037 loss per share (vs AU$0.012 loss in FY 2021) Full year 2022 results: AU$0.037 loss per share (down from AU$0.012 loss in FY 2021). Revenue: AU$6.54m (down 7.0% from FY 2021). Net loss: AU$2.05m (loss widened 320% from FY 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Aug 31
Global Health Limited Announces Contract End of Paul Reining as CFO Global Health Limited announced the end of the contract under which Paul Reining provided CFO-related consulting services. Paul joined Global Health in a consulting capacity to assist with the structuring of an effective finance team and processes. He has achieved this and provided Global Health with an appropriate structure and discipline to underpin the ongoing performance of the finance team. Aankondiging • Aug 15
Global Health Limited Appoints Robin Armstrong as Regional Chief Executive, Asia Pacific in Singapore Global Health Limited Appointment of Mr. Robin Armstrong as Regional Chief Executive, Asia Pacific in Singapore- Asia Pacific Focus. Mr. Robin Armstrong has been engaged as Regional Chief Executive, ASEAN, based out of the Singapore office. Mr. Armstrong will be focused on expanding B2B partnerships and client growth across the ASEAN region as well as helping facilitate Global Health's expansion into these key strategic markets. Mr. Armstrong is a Chartered Insurer (UK) and an experienced senior executive who has worked across Risk Management, Insurance and Health industries in Asia, United Kingdom, Australia, and New Zealand. He has successfully led, transformed, and scaled Insurance and Digital Health growth strategy across the ASEAN region. He will help drive Global Health's innovative Health & Wellness strategy in the ASEAN region, delivering healthcare thought leadership and new value achieved through connecting Clinicians and Consumers. Aankondiging • Jul 07
Global Health Limited Appoints Steven Strange as Non-Executive Director Global Health Limited announced the appointment of Mr. Steven Strange as a Non-Executive Director. Steven is a full member of the Australian Computer Society, Member of the Australian Institute of Company Directors and holds Computing and Law qualifications from Monash University including a master's degree in Information Science. Mr. Strange was the Founder and Executive Director of Health Metrics. He also recently successfully completed the sale of HM to Private Equity interests. Mr. Strange brings over 30 years of leadership experience to the Board at Global Health at a very opportune and pivotal time, where the Company seeks to significantly grow its business both domestically and in its positioning in the Asia Pacific Region. The ongoing digitization of the healthcare sector, fast tracked by the worldwide pandemic, also highlights why the skillset of Mr. Strange will be a very welcome addition to the Board at this time. At HM, this experience was clearly demonstrated where Mr. Strange directed and oversaw the execution of HM's global strategy. Amongst other things, this involved taking technology products to local and international markets. Via this process, Mr. Strange has developed a sound understanding of health care models, on a global basis. Aankondiging • Jun 30
Global Health Announces Retirement of Rob Knowles AO as Non-Executive Director, effective from 30th June 2022 Global Health Limited announced the retirement of Rob Knowles AO effective from 30th June 2022. Global Health acknowledges the significant contribution made by longstanding Board member, Mr. Robert Knowles AO as Non-Executive Director. Executive Departure • Nov 29
Chief Financial Officer Ershad Ali has left the company On the 29th of November, Ershad Ali's tenure as Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Ershad's name. Ershad is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • Oct 04
Full year 2021 earnings released: AU$0.012 loss per share (vs AU$0.005 loss in FY 2020) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: AU$7.03m (up 13% from FY 2020). Net loss: AU$488.0k (loss widened 144% from FY 2020). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 02
Full year 2021 earnings released: AU$0.012 loss per share (vs AU$0.002 loss in FY 2020) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: AU$7.48m (up 20% from FY 2020). Net loss: AU$496.5k (loss widened AU$436.4k from FY 2020). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Aankondiging • Jun 15
Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 7.814 million. Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 7.814 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,079,280
Price\Range: AUD 0.555
Transaction Features: Subsequent Direct Listing Is New 90 Day High Low • Feb 17
New 90-day low: AU$0.40 The company is down 17% from its price of AU$0.48 on 19 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 31% over the same period. Aankondiging • Nov 17
Global Health Limited Wins a Contract for Up to 10 Years with the Government of Western Australia's Mental Health Commission Global Health Limited has been awarded a contract for up to 10 years with the Government of Western Australia's Mental Health Commission (WA MHC) for the implementation of MasterCare EMR. Key Highlights: Initial $850,000 in first year revenue for implementation, services and first year subscription; Hosted Implementation of MasterCare Electronic Medical Record (EMR), MasterCare Dashboards-as-a-Service and ReferralNet Secure Messaging platform; Scheduled to go-live on 1 July with a 5-year term plus 3 options for a further 5-year extension; Includes upgrade path to MasterCare+ SaaS platform over the term. The WA Mental Health Commission are responsible for a network of mental health, drug and alcohol services for the State which are purchased from a range of providers including public Health Service Providers, a wide range of non-government organizations and private service providers. Global Health's MasterCare platform will enable the WA Mental Health Commission to meet the key State and Federal reporting requirements for Alcohol and Other Drug Treatment Services. With the solution becoming W MHC's core EMR solution for managing the treatment of clients and enabling users to connect to critical infrastructure such as the Government's MyHealthRecord and comply with other Digital Health initiatives such as Secure Messaging and ePrescribing. Is New 90 Day High Low • Nov 16
New 90-day high: AU$0.60 The company is up 122% from its price of AU$0.27 on 12 August 2020. The Australian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 25% over the same period. Is New 90 Day High Low • Oct 26
New 90-day high: AU$0.41 The company is up 32% from its price of AU$0.31 on 28 July 2020. The Australian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 25% over the same period.